Calistoga Pharmaceuticals, the Seattle-based biotech company, said today that its lead drug in development was able to at least partially shrink tumors in 12 of the first 24 patients with blood cancers in a clinical trial. The data were presented today at the European Hematology Association meeting in Berlin, Germany. This finding buttresses some more preliminary results we reported on last week from the American Society of Clinical Oncology, in which six of the first 12 patients on the Calistoga drug had partial tumor shrinkage.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
